Hexylresorcinol Clinical Trials

Size	Price	Qty
100mg	USD 147

Clinical Trials

A clinical trial sponsored by industry entity Sytheon Ltd. evaluated the dermatological utility of topical hexylresorcinol for photoaging mitigation. This completed, randomized, double-blind study—categorized as Phase Not Applicable—compared the compound's efficacy directly against hydroquinone in individuals with photoaged skin. Overall, clinical research on hexylresorcinol centers specifically on evaluating its topical effectiveness for photoaging.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04345094	Completed	Photoaging	Sytheon Ltd.	2019-07-01	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Hexylresorcinol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Hexylresorcinol directly binds to and potently inhibits tyrosinase activity, blocking both monophenolase and diphenolase catalytic functions to prevent downstream enzymatic melanin biosynthesis. By restricting epidermal pigment synthesis and cellular hyperpigmentation, this target-specific inhibition underlies its functional utility in clinical protocols directed at mitigating skin photoaging.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).